CureDuchenne Invests in Satellos to Advance a Mutation-Independent Duchenne Therapy
Link to press release
CureDuchenne is pleased to announce that it has participated in the Satellos Bioscience public offering, supporting the company’s $57.2 million financing to advance its Duchenne muscular dystrophy program through clinical development. The funds will support ongoing and planned clinical trials of SAT-3247, an orally administered experimental therapeutic designed to address deficits in muscle repair and regeneration associated with Duchenne.
This investment reflects CureDuchenne’s continued commitment to accelerating promising therapies through CureDuchenne Ventures, which focuses on strategically funding early-stage programs with strong scientific rationale and the potential to benefit the Duchenne community.
Supporting Innovation Through CureDuchenne Ventures
CureDuchenne Ventures was established to help bridge the gap between early discovery and clinical development, a particularly challenging phase for novel Duchenne therapies. By investing in companies like Satellos, CureDuchenne works to de-risk innovative approaches and help move them more efficiently toward patients.
“Through CureDuchenne Ventures, we are intentional about supporting early-stage programs that are grounded in strong science and have the potential to address unmet needs across the Duchenne population,” said Debra Miller, Founder and CEO of CureDuchenne. “Satellos’ approach stood out because it targets a fundamental biological process in Duchenne, muscle repair and regeneration, and could complement existing and future therapies. Our investment reflects our long-term commitment to advancing early-stage research with real promise for the Duchenne community.”
A Dystrophin-Independent Approach to Duchenne
SAT-3247 represents a novel therapeutic strategy that is independent of dystrophin restoration. Rather than targeting the dystrophin gene itself, the therapy is designed to improve the body’s ability to repair and regenerate muscle, a process that is impaired in Duchenne muscular dystrophy.
Because this approach does not depend on a specific dystrophin mutation, it could theoretically be applicable to individuals with any type of Duchenne mutation. If successful, SAT-3247 could be used as a stand-alone therapy or in combination with dystrophin-restoring treatments such as gene therapy or exon-skipping approaches.
This strategy could be a game changer, especially for individuals who already have muscle damage, where improving regeneration could help preserve muscle function and slow disease progression.
Advancing Clinical Development
Satellos is advancing SAT-3247 through clinical development, with a Phase 2 clinical trial currently recruiting individuals with Duchenne muscular dystrophy. This study will further evaluate the safety and potential effectiveness of the therapy in people living with Duchenne.
More information about the Phase 2 trial, including eligibility criteria and participating sites, is available on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07287189
A Shared Commitment to the Duchenne Community
CureDuchenne’s investment reflects its role in helping ensure that promising research continues moving forward, with families at the center of every decision.
“CureDuchenne continues to play an important role in advancing progress for the Duchenne community,” said Frank Gleeson, Satellos co-founder and CEO. “Their support helps enable innovative approaches like ours as we work toward developing a new therapy for people living with Duchenne.”
As Satellos advances SAT-3247 through clinical trials, CureDuchenne remains focused on its mission to fund innovative science, support families, and accelerate the development of therapies that have the potential to improve outcomes for everyone living with Duchenne.
The post CureDuchenne invests in Satellos as it raises $57.2M to advance their Duchenne program through clinical trials appeared first on CureDuchenne.